Certain Cancer Patients at Risk of COVID-19 Vaccine Failure
NOTE: This press release and the research it describes were published in April 2021. The COVID-19 pandemic is ongoing and clinical recommendations, including those surrounding booster vaccinations, are evolving. Consult your physician for updated clinical guidance.
– People with cancer that affects the blood, bone marrow or lymph nodes are at elevated risk of COVID-19 vaccine
failure, particularly those with chronic lymphocytic leukemia, according to new results from an analysis of UPMC Hillman Cancer Center
The finding prompted University of Pittsburgh School of Medicine
clinician-scientists to issue a cautionary statement in the preprint journal medRxiv, urging such patients and those who interact with them to take the COVID-19 vaccines available, but to continue wearing masks and practicing social distancing, even after full vaccination. They simultaneously are pursuing peer-reviewed publication of the findings.
“As we see more national guidance allowing for unmasked gatherings among vaccinated people, clinicians should counsel their immunocompromised patients about the possibility that COVID-19 vaccines may not fully protect them against SARS-CoV-2,” said senior author Ghady Haidar, M.D.
, UPMC transplant infectious diseases physician and assistant professor in Pitt’s Department of Infectious Diseases
. “Our results show that the odds of the vaccine producing an antibody response in people with hematologic malignancies are the equivalent of a coin flip.”
Haidar cautioned that a negative antibody test does not necessarily mean that the patient lacks protection from the virus. At this time, UPMC and the U.S. Centers for Disease Control and Protection do not recommend repeat or booster vaccinations for previously vaccinated people, even if they test negative for antibodies.
are a classification of non-solid tumor cancers, including leukemias, myelomas and lymphomas. These patients have a greater than 30% risk of death if they contract COVID-19
and often receive antibody-depleting therapies, which means they should be prioritized for COVID-19 vaccination. However, they were excluded from COVID-19 mRNA vaccine trials, so data on the vaccines’ effectiveness are nonexistent.
Approximately three weeks after their final vaccination, 67 patients with hematologic malignancies who had been vaccinated with either the Pfizer or Moderna COVID-19 two-dose vaccines had their blood tested. Haidar and his colleagues found that more than 46% of the participants had not produced antibodies against SARS-CoV-2.
Moreover, only three in 13 patients with chronic lymphocytic leukemia
(CLL)—a slowly progressing cancer of the blood and bone marrow—produced measurable antibodies, even though 70% of them weren’t undergoing any form of cancer therapy.
“This lack of response was strikingly low,” said Mounzer Agha, M.D.
, the study’s lead author and a hematologist at UPMC Hillman Cancer Center. “We’re still working to determine why people with hematologic malignancies—particularly those with CLL—have a lower antibody response and if this low response also extends to patients with solid tumors.”
The team did not find a link between cancer therapy and antibody levels to indicate why some of the patients did not mount an adequate immune response to the vaccine. As expected, however, older patients were less likely to produce antibodies compared to younger patients.
“It’s critically important for these patients to be aware of their continued risk and to seek prompt medical attention if they have COVID-19 symptoms, even after vaccination,” Agha added. “They may benefit from outpatient treatments, such as monoclonal antibodies, before the illness becomes severe.”
Additional authors on this research are Maggie Blake, R.N., Charles Chilleo and Alan Wells, M.D., D.M.Sc., all of UPMC or Pitt.
PHOTO INFO: (click images for high-res versions)
CREDIT: University of Pittsburgh
CAPTION: Ghady Haidar, M.D., UPMC transplant infectious diseases physician and assistant professor in Pitt’s Department of Infectious Diseases.
CAPTION: Mounzer Agha, M.D., the study’s lead author and a hematologist at UPMC Hillman Cancer Center.